Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?

Breast Cancer Research and Treatment

Volumn 147, Issue 3, 2014, Pages 617-629

  Sheridan, Wilson ^a   Scott, Tyldesley ^a   Caroline, Speers ^a   Yvonne, Zheng ^a   Vanessa, Bernstein ^a   David, Voduc ^a   Karen, Gelmon ^a   Stephen, Chia ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Early stage breast cancer; Luminal; Prognostic features; Subtypes; Young women

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREMENOPAUSE; PROGNOSIS; RECURRENCE FREE SURVIVAL; BREAST NEOPLASMS; CANADA; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRITISH COLUMBIA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84918593128     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3125-1     Document Type: Article

References (38)

1. El Saghir NS, Seoud M, Khalil MK et al (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6:194. doi:10.1186/1471-2407-6-194
2. de la Rochefordiere A, Asselain B, Campana F et al (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039–1043
3. Bharat A, Aft RL, Gao F et al (2009) Patient and tumor characteristics associated with increased mortality in young women (
4. Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol 36:237–249. doi:10.1053/j.seminoncol.2009.03.001;10.1053/j.seminoncol.2009.03.001
5. Anders CK, Fan C, Parker JS et al (2011) Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29:e18–20. doi:10.1200/JCO.2010.28.9199;10.1200/JCO.2010.28.9199
6. Collins LC, Marotti JD, Gelber S et al (2012) Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 131:1061–1066. doi:10.1007/s10549-011-1872-9;10.1007/s10549-011-1872-9
7. Colleoni M, Rotmensz N, Peruzzotti G et al (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497–1503. doi:10.1093/annonc/mdl145
8. Smith BD, Jiang J, McLaughlin SS et al (2011) Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 29:4647–4653. doi:10.1200/JCO.2011.35.8408
9. Brenner H, Francisci S, de Angelis R et al (2009) Long-term survival expectations of cancer patients in Europe in 2000–2002. Eur J Cancer 45:1028–1041. doi:10.1016/j.ejca.2008.11.005
10. Verdecchia A, Guzzinati S, Francisci S et al (2009) Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 45:1042–1066. doi:10.1016/j.ejca.2008.11.029
11. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792
12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0
13. Bria E, Nistico C, Cuppone F et al (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106:2337–2344. doi:10.1002/cncr.21886
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
15. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492
16. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098
17. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. doi:10.1073/pnas.0932692100
18. Cancello G, Maisonneuve P, Rotmensz N et al (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974–1981. doi:10.1093/annonc/mdq072;10.1093/annonc/mdq072
19. Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. doi:10.1200/JCO.2007.14.2471;10.1200/JCO.2007.14.2471
20. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728. doi:10.1002/cncr.22618
21. Morrison DH, Rahardja D, King E et al (2012) Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer 107:382–387. doi:10.1038/bjc.2012.219;10.1038/bjc.2012.219
22. Aebi S, Gelber S, Castiglione-Gertsch M et al (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874
23. Goldhirsch A, Gelber RD, Yothers G et al (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30:44–51
24. Kim EK, Noh WC, Han W et al (2011) Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg 35:1244–1253. doi:10.1007/s00268-011-1071-1;10.1007/s00268-011-1071-1
25. Ahn SH, Son BH, Kim SW et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368. doi:10.1200/JCO.2006.10.3754
26. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376. doi:10.1158/1078-0432.CCR-07-1658;10.1158/1078-0432.CCR-07-1658
27. Partridge AH, Wang PS, Winer EP et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606
28. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128. doi:10.1200/JCO.2009.25.9655;10.1200/JCO.2009.25.9655
29. Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537. doi:10.1007/s10549-010-1132-4
30. Swain SM, Jeong JH, Geyer CE Jr et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053–2065. doi:10.1056/NEJMoa0909638;10.1056/NEJMoa0909638
31. Parulekar WR, Day AG, Ottaway JA et al (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5. J Clin Oncol 23:6002–6008
32. Pagani O, O’Neill A, Castiglione M et al (1998) Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640
33. Petrek JA, Naughton MJ, Case LD et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24:1045–1051
34. Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769–5779
35. Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. doi:10.1056/NEJMoa1404037
36. Berger NA (2014) Obesity and cancer pathogenesis. Ann N Y Acad Sci 1311:57–76. doi:10.1111/nyas.12416
37. Pan H, Gray, Richard G on behalf of the Early Breast Cancer Trialists’ Collaborative Group (2014) Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. JCO 32:abstract 503
38. Partridge AH, Gelber S, Piccart-Gebhart MJ et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31:2692–2698. doi:10.1200/JCO.2012.44.1956;10.1200/JCO.2012.44.1956